

**Clinical Trials of Parkinson’s Disease Drug Therapies
with Primary Completion Date within 6 months of 31-Mar-2023**

trial data: ClinicalTrials.gov

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Primary Completion Date	Completion Date
NCT04831281	ATH-1017	Athira Pharma	Enhances Hepatocyte Growth Factor activity	Phase 2	ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)	28	1-Apr-2023	1-May-2023
NCT03775096	Carvedilol	Cedars Sinai	Adrenergic blocker	Phase 2	Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)	15	1-May-2023	1-May-2023
NCT04802733	MSK-DA01	Memorial Sloan Kettering Cancer Center	Human ESC-derived neural precursor cells	Phase 1	Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease	12	1-May-2023	1-May-2024
NCT04978597	Opicapone	Neurocrine	Catechol-O-methyltransferase (COMT) inhibitor	Phase 3	Early ParkinSon with L-DOPA/DDCI and OpicapoNe (EPSILON Study)	324	1-May-2023	1-May-2023
NCT03568968	Nicotinamide riboside	Haukeland University Hospital	Nicotinamide riboside	Not Applicable	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	400	15-May-2023	15-Mar-2024
NCT03947216	Pimavanserin	Strasbourg University Hospital	Inverse agonist/antagonist of 5HT2a receptors	Phase 2	Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.	130	31-May-2023	31-Jul-2023
NCT03968133	Ecologic BARRIER 849 (Probiotic)	British Columbia University	Probiotic	Phase 2	Treating Anxiety in Parkinson's Disease With a Multi-Strain Probiotic	61	31-May-2023	1-Dec-2023
NCT04251585	Nasal insulin	HealthPartners Institute	Intra-nasal insulin	Phase 2	Intranasal Insulin in Parkinson's Disease	30	1-Jun-2023	1-Jul-2023
NCT04643327	Levetiracetam	Queensland University	Anti-epileptic	Phase 2	Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease	28	1-Jun-2023	1-Dec-2023
NCT05104463	CST-103 and CST-107	CuraSen Therapeutics	Restores brain homeostasis	Phase 2	A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease	60	1-Jun-2023	1-Dec-2023

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Primary Completion Date	Completion Date
NCT04273932	Lithium	Buffalo University	Protein kinase C inhibitor (treatment for bipolar disorder)	Phase 1	Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	19	15-Jun-2023	1-Aug-2023
NCT03413384	Ceftriaxone	Brainx	Ceftriaxone	Phase 2	To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia	106	30-Jun-2023	31-Dec-2023
NCT03446807	Droxidopa	Loma Linda University/Lundbeck	L-threo-dihydroxyphenylserine	Phase 2	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	0	1-Jul-2023	1-Jul-2023
NCT04651153	UCB7853	UCB and Neuropore	aSN antibody	Phase 1	A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)	57	21-Jul-2023	21-Jul-2023
NCT05435755	Human Amniotic Epithelial Stem Cells	Shanghai iCELL Biotechnology Co., Ltd	Human Amniotic Epithelial Stem Cells	Early Phase 1	Precise Transplantation of hAESC's Into the Ventricle for Parkinson's Disease.	12	30-Jul-2023	30-Aug-2023
NCT04857359	Dipraglurant	Addex Therapeutics	mGluR5 negative allosteric modulator	Phase 2 Phase 3	Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy	140	1-Aug-2023	1-Aug-2023
NCT05471609	Buccal levodopa/carbidopa	University of Minnesota	Levodopa/Carbidopa Sachets for Buccal delivery	Early Phase 1	Sustained Release Oral Formulation for Treatment of Parkinson's Disease	6	2-Aug-2023	2-Aug-2023
NCT04226248	Rivastigmine	Bristol University	Cholinesterase inhibitor	Phase 3	CHIEF PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)	600	30-Aug-2023	30-Nov-2023
NCT03149809	Solifenacin	Astellas Pharma	Antimuscarinic bladder relaxant	Phase 3	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	90	31-Aug-2023	30-Sep-2023
NCT02726386	ND0612	Mitsubishi Tanabe/Neuroderm	Sub-cutaneous L-DOPA	Phase 2	A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion	210	1-Sep-2023	1-Oct-2023
NCT04332276	DIVE	Lille University Hospital/InBrain Pharma	Intra-cerebroventricular dopamine	Phase 1 Phase 2	Dopaminergic restauration by intraVentriculaire Administration	20	1-Sep-2023	1-Sep-2023
NCT05318937	SAGE-718	Sage Therapeutics	NMDA receptor modulator	Phase 2	A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment	76	1-Sep-2023	1-Sep-2023

ClinicalTrials.gov identifier (NCT)	Agent	Company / Sponsor	Agent Description	Phase	Trial Title	Enrollment	Primary Completion Date	Completion Date
NCT05435729	DSP 9632P	Sumitomo Pharma Co., Ltd	Transdermal levodopa	Phase 1	A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease	20	30-Sep-2023	30-Sep-2023
NCT05424276	iKT-148009	Inhibikase Therapeutics	c-Abl kinase inhibitor	Phase 2	A Randomized, Double-Blind, Placebo-Controlled Trial of iKT-148009 in Untreated Parkinson's Disease	120	30-Sep-2023	31-Oct-2023